Consolidated Portfolio Review Corp Dexcom Inc Transaction History

Consolidated Portfolio Review Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$110.31 - $140.45 $1,213 - $1,544	11 Added 0.39%	2,824 $320 Million
Q1 2024 Apr 30, 2024	BUY	$114.22 - $140.1 $23,415 - $28,720	205 Added 7.86%	2,813 $390 Million
Q4 2023 Jan 29, 2024	SELL	$75.49 - $124.16 $2,189 - $3,600	-29 Reduced 1.1%	2,608 $324 Million
Q3 2023 Nov 13, 2023	BUY	$86.06 - $137.93 $2,495 - $3,999	29 Added 1.11%	2,637 $246 Million
Q1 2023 May 11, 2023	BUY	$104.0 - $122.92 $271,232 - $320,575	2,608 New	2,608 $303 Million

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Consolidated Portfolio Review Corp, based on Form 13F filings with the SEC.

Stay updated on Consolidated Portfolio Review Corp with notifications on news.